FDA Brief

Warning letters Drugs

FDA warning letter to

Mohawk Laboratories Division of NCH Corporation

High riskIssued Jan 18, 2023Posted Jan 31, 2023Division of Pharmaceutical Quality Operations II

FDA warns Mohawk Laboratories that its hand sanitizer contained unacceptable acetaldehyde and acetal impurities.

What happened

FDA laboratory testing of three lots of Mohawk's Alcohol Antiseptic, 80% Topical Solution, Hand Sanitizer, and impurity results the firm supplied for additional lots showed acetaldehyde and acetal at unacceptable levels. FDA said the levels were above the USP limit for alcohol and showed quality assurance was not following current good manufacturing practice (CGMP), the required quality rules for drug manufacturing. The firm recalled the product nationwide on December 9, 2022.

What FDA found

  1. The hand sanitizer was contaminated with acetaldehyde and acetal at unacceptable levels, which FDA said showed the company's quality assurance was not working under CGMP.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. The company did not have a specification for acetaldehyde and acetal for alcohol, a significant component of the drug product.

    21 CFR 211.160(b)
  3. The company did not test each finished batch for acetaldehyde and acetal as required.

    21 CFR 211.165
  4. The company's described methods, facilities, or controls for making drugs did not conform to CGMP.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

Respond in writing within 15 working days describing what the company has done to correct violations and prevent recurrence; if corrective actions are not complete, give reasons and a completion schedule. If the company resumes drug manufacturing, it must notify FDA before resuming and should use a qualified CGMP consultant.

Who should pay attention

  • distributors and retailers of Mohawk hand sanitizer
  • other OTC hand sanitizer manufacturers
  • drug quality teams that buy alcohol ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. TSP Solutions Pte. Ltd.

    FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.

    High risk
  3. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk